An interventional study of Sirolimus Coated PTCA Balloon Catheter(Genoss® SCB) and Paclitaxel Coated PTCA Balloon Catheter(SeQuent® Please NEO) in Coronary Arterial Disease (CAD), sponsored by Genoss Co., Ltd.. Enrolling by invitation at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2025-09-08.
Sponsored by Genoss Co., Ltd. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The objective of this study is to evaluate the safety and effectiveness of Genoss® SCB by comparing in-segment late lumen loss (LLL) to the control group (SeQuent® Please NEO) at 6 months in patients with coronary stent-in-stent restenosis (ISR) with a reference vessel diameter of 2.0-4.0 mm.
This pivotal study is a randomized controlled trial to compare with the control group (SeQuent® Please NEO), and will recruit 94 patients with in-stent restenosis (ISR) from 9 institutions. The test group (Genoss® SCB) and the control group (SeQuent® Please NEO) will be randomly assigned 1:1, and all patients will be followed up at 1, 6, and 12 months after the procedure. The primary endpoint is to evaluate in-segment late lumen loss by quantitative coronary angiography (QCA) by an independent assessor at 6 months after the procedure.
Genoss Co., Ltd. is the lead sponsor of 18 studies on the registry; 11 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects with a maximum of two ISR lesions, with visually estimated significant coronary artery stenosis on quantitative coronary angiography analysis (QCA) meeting one of the following criteria:
Exclusion Criteria:
[Exclusion Criteria Based on QCA and Pre-Dilatation Assessment of ISR Lesions]
Subjects requiring CABG based on any of the following:
Subjects for whom pre-dilatation is not feasible or has failed, making application of the device difficult due to any of the following:
After lesion pre-dilatation, if any of the following are present:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Sirolimus Coated PTCA Balloon Catheter
Device: Sirolimus Coated PTCA Balloon Catheter(Genoss® SCB)
Paclitaxel Coated PTCA Balloon Catheter
Device: Paclitaxel Coated PTCA Balloon Catheter(SeQuent® Please NEO)
Drug Coated Balloon
Drug Coated Balloon
In-segment late lumen loss after procedure
In-segment refers to a portion including within 5 mm of each of the distal and proximal portions at the boundary of the inserted stent. Therefore, in-segment late lumen loss (LLL) is defined as the difference (mm) in the minimum lumen diameter (MLD) within the segment at 6 months from baseline.
Time frame: at 6 months after procedure
In-stent late lumen loss after procedure
In-stent refers to a portion between each of the distal and proximal portions. Therefore, in-stent late lumen loss (LLL) is defined as the difference (mm) in the minimum lumen diameter (MLD) within the segment at 6 months from baseline. This is assessed by an independent evaluator using quantitative coronary angiography analysis (QCA) imaging.
Time frame: at 6 months after procedure
Target Lesion Failure (TLF), %
Target lesion failure is defined as a composite of cardiac death, target vessel-related myocardial infarction (TV-MI), and target lesion revascularization (TLR).
Time frame: at 1 month, 6 months, and 12 months after procedure
Patient-oriented composite endpoint (POCE), %
POCE is defined as a composite of all-cause death, any myocardial infarction (MI), any revasularization or stroke.
Time frame: at 1 month, 6 months, and 12 months after procedure
Device success rate, %
Device success rate is defined as successful delivery of the device to the target lesion during the procedure, normal inflation, deflation, and catheter withdrawal of the without balloon rupture.
Time frame: Immediately after the procedure
Procedural success rate, %
The definition of procedural success includes the of device success, freedom adverse events in-hospital \[cardiovascular death, target lesion revascularization, peri-procedural myocardial infarction, any stroke, and BARC 3-5 bleeding\], and freedom from bail-out stenting.
Time frame: up to 24 hours
Binary restenosis rate, %
defined as a in-segment diameter stenosis ≥ 50% at angiographic follow-up
Time frame: at 6 months after procdure
Cardiac Death, %
Death caused by acute MI, Sudden cardiac, including unwitnessed, death, Death resulting from heart failure, Death caused by stroke, Death caused by cardiovascular procedures, Death resulting from cardiovascular haemorrhage (haemorrhage deriving from cardiac and/or vascular disease/injuries)
Time frame: at 1 month, 6 months, and 12 months after procedure
All-cause death, %
Incidence rate of all-cause death including cardiac death.
Time frame: at 1 month, 6 months, 12 months after procedure
Target vessel myocardial infarction (TV-MI), %
Incidence rate of target vessel myocardial infarction
Time frame: at 1 month, 6 months, and 12 months after procedure
Myocardial infarction (MI), %
Incidence rate of all myocardial infarction
Time frame: at 1 month, 6 months, and 12 months after procedure
Ischemia-driven target lesion revascularization (ID-TLR), %
Target lesion revascularization is defined as a repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion.
Time frame: at 1 month, 6 months, and 12 months after procedure
Ischemia-driven target vessel revascularization (ID-TVR), %
Target vessel revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel.
Time frame: at 1 month, 6 months, and 12 months after procedure
Revascularization, %
Revascularizations are defined according to the vessel/lesion treated and are identified as target or non-target, based on the initial site of the treatment.
Time frame: at 1 month, 6 months, and 12 months after procedure
Stent thrombosis
Stent thrombosis will be assessed and classified according to the definitions established by the Academic Research Consortium-2 (ARC-2). Stent thrombus is classified based on how the diagnosis is confirmed. These classifications include definite, and probable stent thrombosis. Definite stent thrombosis Requires confirmation of stent thrombosis on angiography. Probable stent thrombosis Consider if there is active ischemia on electrocardiogram (EKG) or stress in the distribution of prior stent and absence of significant coronary lesion on angiography. Timing may be divided between acute, subacute, early, and late. When classified as early, or late: Early stent thrombosis occurs within one month of initial placement. Late stent thrombosis occurs between 1 and 12 months of initial placement. Early stent thrombosis is divided between acute or subacute: Acute thrombosis occurs within 24 hours of initial placement. Subacute thrombosis occurs between 24 hours to one month of initial place
Time frame: at 1 month, 6 months, and 12 months after procedure
Stroke, %
Neuro-ARC definitions (according to ARC-2 criteria)
Time frame: at 1 month, 6 months, and 12 months after procedure
Major bleeding BARC type III to V, %
Major bleeding according to the Bleeding Academic Research Consortium (BARC) scale includes BARC types 3 to 5. Type 3 bleeding encompasses significant bleeding, including overt bleeding with a hemoglobin drop, intracranial hemorrhage, and bleeding requiring surgery or vasoactive agents. Type 4 refers to bleeding related to coronary artery bypass grafting (CABG). Type 5 bleeding is fatal, either probable or definite. BARC Type 3: Significant Bleeding 3a: Overt bleeding plus a hemoglobin drop of 3-5 g/dL. 3b: Overt bleeding plus a hemoglobin drop of 3-5 g/dL, cardiac tamponade, surgical intervention required, or intravenous vasoactive agents used. 3c: Intracranial hemorrhage. BARC Type 5: Fatal Bleeding 5a: Probable fatal bleeding, no definitive cause of death but clinically suspected. 5b: Definite fatal bleeding, confirmed by imaging or autopsy.
Time frame: at 1 month, 6 months, and 12 months after procedure
Abrupt closure/ Sub abrupt closure, %
① Abrupt closure: Defined as a newly developed, significant reduction in blood flow within the target vessel (TIMI grade 0 or 1) that persists and requires an unplanned rescue strategy (including emergency surgery). This must be associated with mechanical dissection of the treated or manipulated vessel, coronary thrombosis, or severe spasm. ② Sub-abrupt closure: Defined as abrupt closure occurring after the index procedure (after the patient has left the procedure room) but before Visit 3 (4 weeks post-procedure).
Time frame: at 1 months after procedure
Started Feb 2025 (actual). Primary completion is estimated for Jul 2026, 17 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Genoss Co., Ltd.